Deep-pocketed investors have adopted a bullish approach towards Moderna MRNA, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Moderna. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 46% bearish. Among these notable options, 9 are puts, totaling $464,954, and 6 are calls, amounting to $230,705.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $230.0 for Moderna during the past quarter.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Moderna's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Moderna's substantial trades, within a strike price spectrum from $130.0 to $230.0 over the preceding 30 days.
Moderna Option Activity Analysis: Last 30 Days
Largest Options Trades Observed:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
MRNA | PUT | SWEEP | BEARISH | 06/07/24 | $7.45 | $6.1 | $6.5 | $157.50 | $130.0K | 313 | 213 |
MRNA | PUT | TRADE | BULLISH | 10/18/24 | $16.45 | $16.25 | $16.3 | $150.00 | $81.5K | 724 | 50 |
MRNA | CALL | TRADE | BEARISH | 03/21/25 | $10.5 | $9.85 | $9.85 | $230.00 | $55.1K | 57 | 57 |
MRNA | CALL | TRADE | BULLISH | 06/20/25 | $48.8 | $44.25 | $48.8 | $130.00 | $53.6K | 56 | 11 |
MRNA | PUT | TRADE | BULLISH | 10/18/24 | $16.25 | $16.0 | $16.1 | $150.00 | $46.6K | 724 | 100 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Present Market Standing of Moderna
- Trading volume stands at 661,225, with MRNA's price down by -1.36%, positioned at $152.58.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 55 days.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.